Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations
THOR 日本亚组 3 期分析:厄达替尼治疗晚期或转移性尿路上皮癌和成纤维细胞生长因子受体改变
期刊:International Journal of Clinical Oncology
影响因子:2.8
doi:10.1007/s10147-024-02583-3
Matsubara, Nobuaki; Miura, Yuji; Nishiyama, Hiroyuki; Taoka, Rikiya; Kojima, Takahiro; Shimizu, Nobuaki; Hwang, Jason; Ote, Tatsuya; Oyama, Ryo; Toyoizumi, Kiichiro; Mukhopadhyay, Sutapa; Triantos, Spyros; Deprince, Kris; Loriot, Yohann